AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer
2015; American Association for the Advancement of Science; Volume: 7; Issue: 314 Linguagem: Inglês
10.1126/scitranslmed.aac5272
ISSN1946-6242
AutoresDavid S. Hong, Razelle Kurzrock, Youngsoo Kim, Richard Woessner, Anas Younes, John Nemunaitis, Nathan Fowler, Tianyuan Zhou, Joanna Schmidt, Minji Jo, Samantha J. Lee, Mason Yamashita, Steven G. Hughes, Luis Fayad, Sarina A. Piha‐Paul, Murali V.P. Nadella, Morvarid Mohseni, Deborah Lawson, Corinne Reimer, David C. Blakey, Xiaokun Xiao, Jeff Hsu, Alexey S. Revenko, Brett P. Monia, A. Robert MacLeod,
Tópico(s)Cytokine Signaling Pathways and Interactions
ResumoSystemically administered antisense oligonucleotide AZD9150 inhibits STAT3 and shows anticancer activity in preclinical models and patients.
Referência(s)